Clinical trial Recruiting at 1 site Phase1; Phase2 Interventional Ages 40 and up

Microbiota Interventions for Accelerated Aging in People with HIV on Alcohol

Official title: Geroprotective Precision Medicine Strategies in PWH That Use Alcohol

Run by Louisiana State University Health Sciences Center in New Orleans · NCT07462767 · Data updated 2026-11-12

This study tests whether two safe dietary supplements—Limosilactobacillus reuteri and blueberry extract—can affect immune aging markers in people with HIV who recently used alcohol.

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Ages40 Years and up
SexAll
Enrollment160 (estimated)
SponsorLouisiana State University Health Sciences Center in New Orleans
Academic / other
Locations1 site (New Orleans, Louisiana)
StatusRecruiting
StartedSeptember 1, 2026
Main results expectedDecember 1, 2029
Study endsDecember 1, 2029
Registry record updatedOctober 29, 2026
Trial IDNCT07462767 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults ≥40 years with HIV, recent alcohol use (≥42 g in the prior week and positive EtG), and no probiotic use or recent antibiotics/immunosuppressants.

Probably not a fit

Participants with conditions or medications that interfere with immune aging markers or who cannot comply with study procedures may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this randomized, double-blind, crossover trial, adults with HIV who have recent alcohol use receive either Limosilactobacillus reuteri or blueberry extract for four weeks, then switch after a six-week washout. The study compares changes in immune senescence biomarkers within the same participant to see which intervention may influence aging-related immune changes. It is a mechanistic study focusing on immune aging rather than disease treatment, using GRAS supplements and a crossover design to control for individual differences. Biospecimens and clinical assessments occur at baseline and week 4 of each intervention period. Recruitment targets HIV care programs and community outreach in New Orleans.

Why it matters

Potential benefit: If successful, the interventions could provide a simple, safe approach to modulate immune aging in people with HIV who drink alcohol.

How similar studies have gone: Prior research has explored microbiota-based approaches for immune and metabolic effects, with mixed but growing evidence supporting microbiome-targeted strategies in immune-related endpoints.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥40 years
* People with HIV
* Recent alcohol use defined as ≥42 grams in the prior week and positive urine ethyl glucuronide (EtG)

Exclusion Criteria:

* Probiotic use in past 3 months
* Recent antibiotics or immunosuppressives
* Allergy to study products
* Pregnancy or breastfeeding
* Inability to comply

Where it's running

  • LSU Health
    New Orleans, Louisiana, United States
    Recruiting

Study contacts

  • Principal investigator: David A Welsh, MD — LSU Health New Orleans
  • Study coordinator: David A Welsh, MD
  • Email: dwelsh@lsuhsc.edu
  • Phone: United States

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.